Category: Bayer HealthCare
Bayer Healthcare cites 5-year data from a study of its Essure device as confirming the safety and effectiveness of the female sterilization procedure.
Here's a look at some of the top Wall Street stories for medical device companies this week: Diabetes: Valeritas sets terms for $75m IPO; New Siemens healthcare unit to start in May; Australia halts trading in GI Dynamics shares; Bayer aims to boost drugs sales, margins over next 3 years
Bayer says it plans to grow its main healthcare division by 6% annually over the next 3 years.
Here's a look at some of the top regulatory stories for medical device companies this week: Olympus sold 'superbug' scopes without our clearance; FDA clears 1 Hospira plant, flags another; GI Dynamics plunges 50% after FDA halts trial; Sunshine Heart stops trial enrollment after patient deaths; Petition accuses Bayer's Conceptus of altering Essure trial data
A citizens petition filed last month with the FDA accuses Bayer subsidiary Conceptus of altering the clinical trial data for its Essure female sterilization device to win pre-market approval from the safety watchdog.
UPDATED March 10, 2015, with comment from Bayer.
Is KKR-backed Panasonic Health a match for the long rumored sale of Bayer's diabetes device business?
(Reuters) - German drugmaker Bayer AG is close to selling its diabetes devices business to KKR-backed Panasonic Healthcare Holdings Co Ltd and the unit could be valued at up to $2.3 billion, Bloomberg news reported.
Bayer is reportedly exploring a sale of its diabetes device business, which could fetch as much as $2.5 billion from interested private equity buyers.
(Reuters) — Bayer (PINK:BAYRY) is considering the sale of its diabetes device business, Bloomberg reported, citing sources.